Journal article

The N3RO trial: a randomised controlled trial of docosahexaenoic acid to reduce bronchopulmonary dysplasia in preterm infants < 29 weeks' gestation

Carmel T Collins, Robert A Gibson, Maria Makrides, Andrew J McPhee, Thomas R Sullivan, Peter G Davis, Marta Thio, Karen Simmer, Victor S Rajadurai



Awarded by NHMRC, Australia

Awarded by NHMRC Fellowships

Funding Acknowledgements

Supported by Project Grant 1022112 from the NHMRC, Australia. Study product is donated by Clover Corporation Limited, Australia. CTC is supported by a MS McLeod Research Fellowship (MS McLeod Research Fund, Women's and Children's Hospital Research Foundation); NHMRC Fellowships support RAG (Senior Principal Research Fellow 1046207), MM (Principal Research Fellow 1061704), PGD (Practitioner Fellow 1059111). The funding bodies had no role in the design of this study and will not have any role during the conduct of the study, data collection, study management, analyses and interpretation of the data or in the writing, review or approval publications. The contents of the published material are solely the responsibility of the authors and do not reflect the views of the NHMRC.